TP53 and ovarian serous adenocarcinoma: PEO1 and PEO4 cells, which both have the missense G224D p53 mutation, were derived from a high grade serous ovarian adenocarcinoma from the same patient at different timepoints in the course of PARP inhibitor treatment.